| Patent application number | Description | Published |
|---|
| 20090118201 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition. | 05-07-2009 |
| 20100055761 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING - The present invention provides methods and compositions for treating various diseases through selective killipg of targeted cells using a combinatorial targeting approach. The invention features protoxin fusion proteins containing a cell targeting moiety and, a modifiable activation moiety which is activated by an activation moiety not naturally operably found in, on, or in the vicinity of a target cell. These methods also include the combinatorial use of two or more therapeutic agents, at minimum comprising a protoxin and a protoxin activator, to target and destroy a specific cell population. | 03-04-2010 |
| 20100063141 | DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE - Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition. | 03-11-2010 |
| 20100215677 | PDZ DOMAIN INTERACTIONS AND LIPID RAFTS - Methods for modulating immune cell signaling are provided. In general such methods involve modulating an interaction between a PDZ protein and a PDZ ligand protein whose interaction affects the composition and/or distribution of lipid rafts in an immune cell. Modulators that enhance or inhibit such interactions are also disclosed, as well as methods of screening for such modulators. | 08-26-2010 |
| 20110021507 | INHIBITING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN - The present invention provides methods, compositions and kits for preventing, inhibiting, reducing and reversing weight gain induced by antipsychotic medications, for example olanzapine and clozapine, by co-administration of an M | 01-27-2011 |
| 20110059504 | ENGINEERED TRANSGLUTAMINASE BARREL PROTEINS - Disclosed herein are methods and compositions related to engineered fragments of the human transglutaminase-related protein family, described herein as engineered transglutaminase barrel proteins (ETBPs), that have utility as high affinity, high selectivity target-binding proteins offering advantages as antibody equivalents for therapeutic, analytical, manufacturing and research purposes. ETBPs differ from naturally occurring human transglutaminase fragments by the addition, deletion, replacement and/or substitution of the naturally occurring amino acid sequence. ETBPs can be easily expressed in prokaryotic cells and in many cases can be purified by a simple solubilization and precipitation method. | 03-10-2011 |
| 20110077212 | THERAPEUTIC USES OF SGLT2 INHIBITORS - Provided are methods of using one or more SGLT2 inhibitors, independently or in combination, for treating edema or reducing fluid retention. The invention also provides methods of using one or more SGLT2 inhibitors for the preparation of a medicament for treating edema or fluid retention. Methods are also provided for treating diabetes with an amount of one or more SGLT2 inhibitors and one or more PPAR-gamma agonists. | 03-31-2011 |
| 20110195952 | TREATING PSYCHOLOGICAL CONDITIONS USING MUSCARINIC RECEPTOR M1 ANTAGONISTS - Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M | 08-11-2011 |
